<p>enGene Holdings Inc.（納斯達克代碼：ENGN - 獲取免費報告）在週三的交易中交易量強勁。交易期間共成交 194,725 股，較前一交易日的 168,385 股增加了 16%。該股最後交易價格為 9.09 美元，之前收盤價為 8.38 美元。</p>
<h2>分析師設定新目標價</h2>
<p>多家研究機構最近對 ENGN 進行了評估。瑞銀集團將 enGene 的目標價從 4.00 美元上調至 10.00 美元，並在 11 月 12 日的研究報告中給予該股 “中性” 評級。Citizens Jmp 將 enGene 的目標價從 18.00 美元上調至 21.00 美元，並在 11 月 12 日的研究報告中給予該股 “市場表現優於大盤” 評級。Raymond James Financial 將 enGene 的評級從 “表現優於大盤” 上調至 “強力買入”，並在 11 月 11 日的研究報告中設定 27.00 美元的目標價。Weiss Ratings 在週五的研究報告中重申了對 enGene 的 “賣出（d-）” 評級。最後，花旗集團在 1 月 5 日的研究報告中重申了對 enGene 的 “市場表現優於大盤” 評級。一位投資分析師給予該股 “強力買入” 評級，七位分析師給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該股目前的平均評級為 “適度買入”，共識目標價為 22.38 美元。</p>
<p><strong>閲讀我們關於 enGene 的最新研究報告</strong></p>
<h2>enGene 價格表現</h2>
<p>該公司 50 日簡單移動平均線為 8.16 美元，200 日簡單移動平均線為 6.42 美元。公司的流動比率為 6.30，速動比率為 6.30，債務與股本比率為 0.09。該公司的市值為 6.0425 億美元，市盈率為-3.99，貝塔值為-0.29。</p>
<p>enGene（納斯達克代碼：ENGN - 獲取免費報告）最近於 12 月 22 日發佈了季度財報。公司報告每股收益（EPS）為（0.73 美元），低於市場共識預期的（0.55 美元）0.18 美元。分析師預計，enGene Holdings Inc.在當前年度將發佈-1.56 的每股收益。</p>
<h2>對 enGene 的對沖基金看法</h2>
<p>幾家機構投資者和對沖基金最近調整了對 ENGN 的持股。Cresset Asset Management LLC 在第二季度收購了 enGene 的新股份，價值約 36,000 美元。Paloma Partners Management Co 在第二季度收購了 enGene 的新股份，價值約 38,000 美元。PFS Partners LLC 在第三季度購買了 enGene 的新股份，價值約 61,000 美元。Raymond James Financial Inc.在第三季度將其在 enGene 的持股增加了 383.6%。Raymond James Financial Inc.現在擁有該公司 10,000 股股票，價值 68,000 美元，此前在上一季度又購買了 7,932 股。最後，Hudson Bay Capital Management LP 在第三季度收購了 enGene 的新股份，價值 76,000 美元。機構投資者和對沖基金持有該公司 64.16% 的股份。</p>
<h2>關於 enGene</h2>
<p>（獲取免費報告）</p>
<p>enGene, Inc 是一家臨牀階段的生物製藥公司，專注於開發基於基因的腫瘤治療藥物。公司的核心技術是 EnGene 遞送載體（EDV）平台，該平台利用非活性、細菌衍生的微細胞直接將治療藥物輸送到腫瘤細胞。通過將靶向遞送與強效藥物結合，enGene 旨在提高癌症治療的精準性和有效性，同時減少非靶向毒性。</p>
<p>通過其 EDV 平台，enGene 已將多個治療候選藥物推進到臨牀前和臨牀階段。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 enGene</li>
<li>將這些代碼輸入您的普通經紀賬户</li>
<li>請勿刪除，立即閲讀</li>
<li>超過 200 萬盎司的定義 - 他們的故事仍在早期</li>
<li>如果您在美國銀行賬户中存放現金……請立即閲讀</li>
<li>什麼費用可以從資本利得税中扣除？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 enGene 嗎？</h2>
<p>在您考慮 enGene 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前……而 enGene 並不在名單上。</p>
<p>雖然 enGene 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ENGN

<p>enGene Holdings Inc.（納斯達克代碼：ENGN）交易量增加了 16%，成交 194,725 股。股價從 8.38 美元上漲至 9.09 美元。分析師們設定了新的價格目標，瑞銀將其目標從 4.00 美元上調至 10.00 美元，Citizens Jmp 將其目標從 18.00 美元上調至 21.00 美元。Raymond James 將該股票評級上調至 “強力買入”，目標價為 27.00 美元。平均評級為 “適度買入”，共識目標為 22.38 美元。enGene 專注於腫瘤學的基因治療，利用其 EDV 平台進行靶向遞送</p>

<p>enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) saw strong trading volume on Wednesday . 194,725 shares traded hands during trading, an increase of 16% from the previous session's volume of 168,385 shares.The stock last traded at $9.09 and had previously closed at $8.38.</p>
<div class="lb-trans"><p>enGene Holdings Inc.（納斯達克代碼：ENGN - 獲取免費報告）在週三的交易中交易量強勁。交易期間共成交 194,725 股，較前一交易日的 168,385 股增加了 16%。該股最後交易價格為 9.09 美元，之前收盤價為 8.38 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of research firms have recently weighed in on ENGN. UBS Group upped their target price on shares of enGene from $4.00 to $10.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, November 12th. Citizens Jmp boosted their target price on enGene from $18.00 to $21.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Wednesday, November 12th. Raymond James Financial upgraded enGene from an &#34;outperform&#34; rating to a &#34;strong-buy&#34; rating and set a $27.00 price target on the stock in a research note on Tuesday, November 11th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of enGene in a research note on Friday. Finally, Citigroup reaffirmed a &#34;market outperform&#34; rating on shares of enGene in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $22.38.</p>
<div class="lb-trans"><p>多家研究機構最近對 ENGN 進行了評估。瑞銀集團將 enGene 的目標價從 4.00 美元上調至 10.00 美元，並在 11 月 12 日的研究報告中給予該股 “中性” 評級。Citizens Jmp 將 enGene 的目標價從 18.00 美元上調至 21.00 美元，並在 11 月 12 日的研究報告中給予該股 “市場表現優於大盤” 評級。Raymond James Financial 將 enGene 的評級從 “表現優於大盤” 上調至 “強力買入”，並在 11 月 11 日的研究報告中設定 27.00 美元的目標價。Weiss Ratings 在週五的研究報告中重申了對 enGene 的 “賣出（d-）” 評級。最後，花旗集團在 1 月 5 日的研究報告中重申了對 enGene 的 “市場表現優於大盤” 評級。一位投資分析師給予該股 “強力買入” 評級，七位分析師給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該股目前的平均評級為 “適度買入”，共識目標價為 22.38 美元。</p>
</div><p><strong>Read Our Latest Research Report on enGene</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 enGene 的最新研究報告</strong></p>
</div><h2>enGene Price Performance</h2>
<div class="lb-trans"><h2>enGene 價格表現</h2>
</div><p>The firm has a 50-day simple moving average of $8.16 and a 200-day simple moving average of $6.42. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The firm has a market cap of $604.25 million, a P/E ratio of -3.99 and a beta of -0.29.</p>
<div class="lb-trans"><p>該公司 50 日簡單移動平均線為 8.16 美元，200 日簡單移動平均線為 6.42 美元。公司的流動比率為 6.30，速動比率為 6.30，債務與股本比率為 0.09。該公司的市值為 6.0425 億美元，市盈率為-3.99，貝塔值為-0.29。</p>
</div><p>enGene (NASDAQ:ENGN - Get Free Report) last released its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). As a group, analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current year.</p>
<div class="lb-trans"><p>enGene（納斯達克代碼：ENGN - 獲取免費報告）最近於 12 月 22 日發佈了季度財報。公司報告每股收益（EPS）為（0.73 美元），低於市場共識預期的（0.55 美元）0.18 美元。分析師預計，enGene Holdings Inc.在當前年度將發佈-1.56 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On enGene</h2>
<div class="lb-trans"><h2>對 enGene 的對沖基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of ENGN. Cresset Asset Management LLC acquired a new stake in enGene during the second quarter worth about $36,000. Paloma Partners Management Co acquired a new stake in shares of enGene during the 2nd quarter worth approximately $38,000. PFS Partners LLC purchased a new position in shares of enGene during the 3rd quarter valued at approximately $61,000. Raymond James Financial Inc. increased its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock valued at $68,000 after purchasing an additional 7,932 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in shares of enGene in the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 64.16% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近調整了對 ENGN 的持股。Cresset Asset Management LLC 在第二季度收購了 enGene 的新股份，價值約 36,000 美元。Paloma Partners Management Co 在第二季度收購了 enGene 的新股份，價值約 38,000 美元。PFS Partners LLC 在第三季度購買了 enGene 的新股份，價值約 61,000 美元。Raymond James Financial Inc.在第三季度將其在 enGene 的持股增加了 383.6%。Raymond James Financial Inc.現在擁有該公司 10,000 股股票，價值 68,000 美元，此前在上一季度又購買了 7,932 股。最後，Hudson Bay Capital Management LP 在第三季度收購了 enGene 的新股份，價值 76,000 美元。機構投資者和對沖基金持有該公司 64.16% 的股份。</p>
</div><h2>About enGene</h2>
<div class="lb-trans"><h2>關於 enGene</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.</p>
<div class="lb-trans"><p>enGene, Inc 是一家臨牀階段的生物製藥公司，專注於開發基於基因的腫瘤治療藥物。公司的核心技術是 EnGene 遞送載體（EDV）平台，該平台利用非活性、細菌衍生的微細胞直接將治療藥物輸送到腫瘤細胞。通過將靶向遞送與強效藥物結合，enGene 旨在提高癌症治療的精準性和有效性，同時減少非靶向毒性。</p>
</div><p>Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.</p>
<div class="lb-trans"><p>通過其 EDV 平台，enGene 已將多個治療候選藥物推進到臨牀前和臨牀階段。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than enGene</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>Do not delete, read immediately</li>
<li>More than 2 million ounces defined - and still early in their story</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 enGene</li>
<li>將這些代碼輸入您的普通經紀賬户</li>
<li>請勿刪除，立即閲讀</li>
<li>超過 200 萬盎司的定義 - 他們的故事仍在早期</li>
<li>如果您在美國銀行賬户中存放現金……請立即閲讀</li>
<li>什麼費用可以從資本利得税中扣除？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in enGene Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 enGene 嗎？</h2>
</div><p>Before you consider enGene, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 enGene 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前……而 enGene 並不在名單上。</p>
</div><p>While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 enGene 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

enGene（NASDAQ:ENGN）交易量大幅增加 - 仍然值得購買嗎？